SCHEMBL3015256

SCHEMBL3015256

Cc1ccc(C)c(-c2csc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4Cl)CC3)n2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.57
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
LMNA P02545 4/20 0.43
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
MAPK1 P28482 2/20 0.42
RAB9A P51151 1/20 0.42
HSD11B1 P28845 1/20 0.41
LPAR1 Q92633 1/20 0.41
LPAR2 Q9HBW0 1/20 0.41
TRPV4 Q9HBA0 1/20 0.40
THRB P10828 1/20 0.40
POLB P06746 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3653691 0.92 AR (0.51) ARNFKB1NFKB2RELALMNA
SCHEMBL3015176 0.92 AR (0.57) ARNFKB1NFKB2RELALMNA
SCHEMBL3023399 0.90 AR (0.55) ARNFKB1NFKB2RELALMNA
SCHEMBL3012748 0.90 AR (0.55) ARNFKB1NFKB2RELALMNA
SCHEMBL3020756 0.89 AR (0.49) ARLMNAALDH1A1SMN1; SMN2MAPT
SCHEMBL3001137 0.89 AR (0.58) ARNFKB1NFKB2RELALMNA
SCHEMBL2999125 0.89 AR (0.58) ARNFKB1NFKB2RELALMNA
SCHEMBL3005755 0.88 AR (0.59) ARNFKB1NFKB2RELALMNA
SCHEMBL3016587 0.88 AR (0.53) ARLMNAALDH1A1MAPTMEN1
SCHEMBL3017021 0.87 SMN1; SMN2 (0.54) ARLMNAALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885NFKB1 1767/4885NFKB2 2341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.